- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1371587-51-7] Cavosonstat
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-109027 |
| Brand: | MCE |
| CAS: | 1371587-51-7 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 299.71 |
| Molecular Formula | C16H10ClNO3 |
| SMILES | ClC(C=C(C(O)=O)C=C1)=C1C2=NC(C=CC(O)=C3)=C3C=C2 |
Summary
In Vitro
Cavosonstat (N91115), a CFTR modulator, promotes cystic fibrosis transmembrane conductance regulator (CFTR) maturation and plasma membrane stability, with a mechanism of action complementary to CFTR correctors and potentiators [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04600778 | GSNOR Therapeutics, Inc. |
Chronic Obstructive Pulmonary Disease (COPD)
|
February 3, 2021 | Phase 2 |
| NCT02227888 | Nivalis Therapeutics, Inc. |
Cystic Fibrosis
|
October 2014 | Phase 1 |
| NCT04129931 | University of North Carolina, Chapel Hill|National Heart, Lung, and Blood Institute (NHLBI) |
Asthma
|
December 19, 2019 | Phase 2 |
| NCT02275936 | Nivalis Therapeutics, Inc. |
Cystic Fibrosis
|
February 2015 | Phase 1 |
| NCT02589236 | Nivalis Therapeutics, Inc.|Medidata Solutions |
Cystic Fibrosis
|
November 2015 | Phase 2 |
| NCT02500667 | Nivalis Therapeutics, Inc.|Davita Clinical Research |
Drug Interaction Potentiation
|
June 2015 | Phase 1 |
| NCT02724527 | Nivalis Therapeutics, Inc. |
Cystic Fibrosis
|
April 2016 | Phase 2 |
| NCT02013388 | Nivalis Therapeutics, Inc. |
Healthy
|
February 2014 | Phase 1 |
| NCT02934139 | Nivalis Therapeutics, Inc. |
Cystic Fibrosis
|
October 2016 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 166.83 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.3366 mL | 16.6828 mL | 33.3656 mL |
| 5 mM | 0.6673 mL | 3.3366 mL | 6.6731 mL |
| 10 mM | 0.3337 mL | 1.6683 mL | 3.3366 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (8.34 mM); Clear solution
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.